These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 25354111)

  • 1. Enzalutamide in metastatic prostate cancer before chemotherapy.
    Beer TM; Tombal B
    N Engl J Med; 2014 Oct; 371(18):1755-6. PubMed ID: 25354111
    [No Abstract]   [Full Text] [Related]  

  • 2. Enzalutamide in metastatic prostate cancer before chemotherapy.
    Froehner M; Wirth MP
    N Engl J Med; 2014 Oct; 371(18):1755. PubMed ID: 25354112
    [No Abstract]   [Full Text] [Related]  

  • 3. Words of wisdom. Re: Enzalutamide in metastatic prostate cancer before chemotherapy.
    Althaus A; Kibel A
    Eur Urol; 2015 Jan; 67(1):174. PubMed ID: 25528395
    [No Abstract]   [Full Text] [Related]  

  • 4. Word of wisdom. Re: enzalutamide in metastatic prostate cancer before chemotherapy.
    Chow K; Murphy DG
    Eur Urol; 2014 Oct; 66(4):785-6. PubMed ID: 25218073
    [No Abstract]   [Full Text] [Related]  

  • 5. Prostate cancer: enzalutamide PREVAILs.
    Payton S
    Nat Rev Urol; 2014 Jul; 11(7):361. PubMed ID: 24934449
    [No Abstract]   [Full Text] [Related]  

  • 6. Further analysis of PREVAIL: enzalutamide use in chemotherapy-naïve men with metastatic castration-resistant prostate cancer.
    Aragon-Ching JB
    Asian J Androl; 2014; 16(6):803-4. PubMed ID: 25080931
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enzalutamide in chemo-naïve castration-resistant prostate cancer: effective for most but not for all.
    Maughan BL; Antonarakis ES
    Asian J Androl; 2014; 16(6):807-8. PubMed ID: 25155108
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enzalutamide in metastatic prostate cancer before chemotherapy.
    Beer TM; Armstrong AJ; Rathkopf DE; Loriot Y; Sternberg CN; Higano CS; Iversen P; Bhattacharya S; Carles J; Chowdhury S; Davis ID; de Bono JS; Evans CP; Fizazi K; Joshua AM; Kim CS; Kimura G; Mainwaring P; Mansbach H; Miller K; Noonberg SB; Perabo F; Phung D; Saad F; Scher HI; Taplin ME; Venner PM; Tombal B;
    N Engl J Med; 2014 Jul; 371(5):424-33. PubMed ID: 24881730
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term Efficacy and Safety Results: Can Enzalutamide Challenge the Dogma of Androgen Deprivation Therapy in Hormone-naïve Prostate Cancer?
    Albiges L; Loriot Y; Massard C; Fizazi K
    Eur Urol; 2015 Nov; 68(5):802-4. PubMed ID: 25922192
    [No Abstract]   [Full Text] [Related]  

  • 10. Enzalutamide, a second generation androgen receptor antagonist: development and clinical applications in prostate cancer.
    Menon MP; Higano CS
    Curr Oncol Rep; 2013 Apr; 15(2):69-75. PubMed ID: 23341368
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enzalutamide in prostate cancer after chemotherapy.
    Berruti A; Generali D; Tampellini M
    N Engl J Med; 2012 Dec; 367(25):2448; author reply 2448-9. PubMed ID: 23252532
    [No Abstract]   [Full Text] [Related]  

  • 12. Role of radiation and androgen deprivation therapy for advanced prostate cancer.
    Jani AB; Rossi PJ
    Curr Probl Cancer; 2015; 39(1):41-7. PubMed ID: 25554467
    [No Abstract]   [Full Text] [Related]  

  • 13. Enzalutamide--a major advance in the treatment of metastatic prostate cancer.
    Vogelzang NJ
    N Engl J Med; 2012 Sep; 367(13):1256-7. PubMed ID: 23013078
    [No Abstract]   [Full Text] [Related]  

  • 14. MDV3100 for the treatment of prostate cancer.
    Mukherji D; Pezaro CJ; De-Bono JS
    Expert Opin Investig Drugs; 2012 Feb; 21(2):227-33. PubMed ID: 22229405
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reappraisal of glucocorticoids in castrate-resistant prostate cancer.
    Sartor O; Parker CC; de Bono J
    Asian J Androl; 2014; 16(5):666. PubMed ID: 24994787
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prostate cancer: enzalutamide impresses in European studies.
    Payton S
    Nat Rev Urol; 2014 May; 11(5):243. PubMed ID: 24776976
    [No Abstract]   [Full Text] [Related]  

  • 17. Chemotherapy and targeted therapies: are we making progress in castrate-resistant prostate cancer?
    Hoffman-Censits J; Fu M
    Semin Oncol; 2013 Jun; 40(3):361-74. PubMed ID: 23806500
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Commentary on: "Enzalutamide monotherapy in hormone-naive prostate cancer: primary analysis of an open-label, single-arm, phase 2 study." Tombal B, Borre M, Rathenborg P, Werbrouck P, Van Poppel H, Heidenreich A, Iversen P, Braeckman J, Heracek J, Baskin-Bey E, Ouatas T, Perabo F, Phung D, Hirmand M, Smith MR. Institut de Recherche Clinique, Université Catholique de Louvain, Brussels, Belgium. Electronic address: bertrand.tombal@uclouvain.be. Aarhus University Hospital, Aarhus, Denmark. Herlev Hospital, Herlev, Denmark. AZ Groeninge Kortrijk, Kortrijk, Belgium. UZ Leuven, Leuven, Belgium. Klinik und Poliklinik für Urologie, RWTH University Aachen, Aachen, Germany. Rigshospitalet, University of Copenhagen, Copenhagen, Denmark. UZ Brussel, Brussels, Belgium. Univerzita Karlova v Praze, Prague, Czech Republic. Astellas Pharma Global Development, Leiden, Netherlands. Astellas Pharma Global Development, Northbrook, IL, USA. Medivation Inc, San Francisco, CA, USA. Massachusetts General Hospital Cancer Center, Boston, MA, USA: Lancet Oncol. 2014 May;15(6):592-600; doi: 10.1016/S1470-2045(14)70129-9. [Epub 2014 Apr 14].
    Trump D
    Urol Oncol; 2016 May; 34(5):248-9. PubMed ID: 25937426
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Re: Christoph A. Von Klot, Markus A. Kuczyk, Axel S. Merseburger. No androgen withdrawal syndrome for enzalutamide: a report of disease dynamics in the postchemotherapy setting. Eur Urol 2014;65:258-9: Enzalutamide withdrawal syndrome: fact or fiction?
    Schrader AJ; Schrader MG; Cronauer MV
    Eur Urol; 2014 Feb; 65(2):e22-3. PubMed ID: 24210913
    [No Abstract]   [Full Text] [Related]  

  • 20. Anti-androgen monotherapy for metastatic prostate cancer.
    Attard G
    Lancet Oncol; 2014 May; 15(6):543-4. PubMed ID: 24739898
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.